Skip to main content
Livermore
Livermore
ZHEN

Affinity Asset Advisors, LLC

SEC CIK
0001773195
Latest filing
Aug 13, 2026

Holdings in Q4 2024

Holdings as of Dec 31, 2024, filed Feb 13, 2025. Long positions only; changes compare share counts with Q3 2024.

Institution overview
Positions
75
−2 vs. Q3 2024
Portfolio value
$640.1M
−$4.42M (−0.7%) vs. Q3 2024
Filed
Feb 13, 2025
SEC
Holdings of Affinity Asset Advisors, LLC in Q4 2024
SecurityClassSharesValue% of portfolioShare changeActionHistory
XENEXenon Pharmaceuticals Inc.COM1,161,237$45.5M7.1%+17,216+1.5%AddedHistory
APGEApogee Therapeutics, Inc.COM931,728$42.2M6.6%+267,530+40.3%AddedHistory
ACLXArcellx, Inc.COMMON STOCK425,000$32.6M5.1%+25,000+6.3%AddedHistory
ALKSAlkermes plc.SHS1,100,000$31.6M4.9%+100,000+10.0%AddedHistory
TEVATeva Pharmaceutical Industries LtdSPONSORED ADS1,400,000$30.9M4.8%00.0%UnchangedHistory
VRNAVerona Pharma plcSPONSORED ADS660,000$30.7M4.8%+10,000+1.5%AddedHistory
MDGLMadrigal Pharmaceuticals, Inc.COM82,500$25.5M4.0%−17,500−17.5%ReducedHistory
CRNXCrinetics Pharmaceuticals, Inc.COM460,000$23.5M3.7%+60,000+15.0%AddedHistory
NUVLNuvalent, Inc.COM285,000$22.3M3.5%−52,500−15.6%ReducedHistory
SYRESpyre Therapeutics, Inc.COM NEW824,328$19.2M3.0%+325,908+65.4%AddedHistory
WVEWave Life Sciences, Inc.SHS1,500,000$18.6M2.9%+100,000+7.1%AddedHistory
CNTACentessa Pharmaceuticals plcSPONSORED ADS1,095,924$18.4M2.9%+130,312+13.5%AddedHistory
VERAVera Therapeutics, Inc.CL A425,000$18.0M2.8%−10,000−2.3%ReducedHistory
NRIXNurix Therapeutics, Inc.COM940,083$17.7M2.8%+79,684+9.3%AddedHistory
MRUSMerus N.V.COM389,241$16.4M2.6%+227,500+140.7%AddedHistory
Coherus Biosciences Inc19249HAB9NOTE 1.500% 4/1–$16.2M2.5%–––
Omeros Corp682143AG7NOTE 5.250% 2/1–$14.6M2.3%–––
ESTAEstablishment Labs Holdings Inc.COM279,445$12.9M2.0%−11,002−3.8%ReducedHistory
ARVNArvinas, Inc.COM630,000$12.1M1.9%+405,000+180.0%AddedHistory
Karyopharm Therapeutics Inc.48576UAA4NOTE 3.000%10/1–$11.9M1.9%–––
INZYInozyme Pharma, Inc.COM3,972,318$11.0M1.7%+1,150,000+40.7%AddedHistory
NAMSNewAmsterdam Pharma Co N.V.ORDINARY SHARES425,000$10.9M1.7%−47,390−10.0%ReducedHistory
AUTLAutolus Therapeutics plcSPON ADS4,500,000$10.6M1.7%00.0%UnchangedHistory
GERNGeron CorpCOM2,250,000$7.96M1.2%+750,000+50.0%AddedHistory
RZLTRezolute, Inc.COM NEW1,575,000$7.72M1.2%−125,000−7.4%ReducedHistory
PRQRProQR Therapeutics N.V.SHS EURO2,825,000$7.49M1.2%+2,825,000NewHistory
ORKAOruka Therapeutics, Inc.COM368,698$7.15M1.1%+18,862+5.4%AddedHistory
AXSMAxsome Therapeutics, Inc.COM75,000$6.35M1.0%−5,000−6.3%ReducedHistory
ERASErasca, Inc.COM2,499,431$6.27M1.0%00.0%UnchangedHistory
SLNOSoleno Therapeutics IncCOM130,000$5.84M0.9%+105,000+420.0%AddedHistory
Travere Therapeutics, Inc.89422GAA5NOTE 2.250% 3/0–$5.74M0.9%–––
ARWRArrowhead Pharmaceuticals, Inc.COM300,000$5.64M0.9%−25,000−7.7%ReducedHistory
BBIOBridgeBio Pharma, Inc.COM200,000$5.49M0.9%−100,000−33.3%ReducedHistory
PTGXProtagonist Therapeutics, IncCOM130,000$5.02M0.8%+130,000NewHistory
MLYSMineralys Therapeutics, Inc.COM350,000$4.31M0.7%00.0%UnchangedHistory
CATXPerspective Therapeutics, Inc.COM NEW1,300,000$4.15M0.6%+800,000+160.0%AddedHistory
AVTXAvalo Therapeutics, Inc.COM NEW550,765$4.09M0.6%+505,765+1,123.9%AddedHistory
FRNMFreenome, Inc.CL A ORD SHS350,000$3.56M0.6%00.0%UnchangedHistory
TVTXTravere Therapeutics, Inc.COM200,000$3.48M0.5%+200,000NewHistory
INSMINSMED IncCOM PAR $.0150,000$3.45M0.5%00.0%UnchangedHistory
NAMSWNewAmsterdam Pharma Co N.V.*W EXP 11/22/202237,935$3.33M0.5%+24,961+11.7%AddedHistory
CMPSCOMPASS Pathways plcSPONSORED ADS850,512$3.21M0.5%+550,000+183.0%AddedHistory
CGEMCullinan Therapeutics, Inc.COM263,817$3.21M0.5%00.0%UnchangedHistory
VRDNViridian Therapeutics, Inc.COM159,614$3.06M0.5%−365,386−69.6%ReducedHistory
MIRMMirum Pharmaceuticals, Inc.COM70,742$2.93M0.5%−4,258−5.7%ReducedHistory
CGONCG Oncology, Inc.COM100,000$2.87M0.4%+100,000NewHistory
TECXTectonic Therapeutic, Inc.COM58,331$2.69M0.4%00.0%UnchangedHistory
BBOTBridgeBio Oncology Therapeutics, Inc.CL A ORD SHS250,000$2.63M0.4%00.0%UnchangedHistory
OACCUOaktree Acquisition Corp. III Life SciencesUNIT 10/04/2029250,000$2.54M0.4%+250,000NewHistory
IMVTImmunovant, Inc.COM100,000$2.48M0.4%−125,000−55.6%ReducedHistory
JBIOJade Biosciences, Inc.COM800,000$2.12M0.3%+200,000+33.3%AddedHistory
PCVXVaxcyte, Inc.COM25,000$2.05M0.3%−25,000−50.0%ReducedHistory
NKTXNkarta, Inc.COM800,000$1.99M0.3%+150,000+23.1%AddedHistory
NXTCNextCure, Inc.COM2,302,598$1.78M0.3%00.0%UnchangedHistory
AVRAnteris Technologies Global Corp.COM300,000$1.67M0.3%+300,000NewHistory
KYMRKymera Therapeutics, Inc.COM40,000$1.61M0.3%+40,000NewHistory
APLSApellis Pharmaceuticals, Inc.COM50,000$1.60M0.2%+50,000NewHistory
RAPTRAPT Therapeutics, Inc.COM1,000,000$1.58M0.2%+1,000,000NewHistory
NARIInari Medical, Inc.Stock25,000$1.28M0.2%−35,000−58.3%ReducedHistory
SVRASavara IncCOM410,586$1.26M0.2%−289,414−41.3%ReducedHistory
OKUROnKure Therapeutics, Inc.COM CL A144,159$1.24M0.2%+144,159NewHistory
BDTXBlack Diamond Therapeutics, Inc.COM559,163$1.20M0.2%+559,163NewHistory
CNTXContext Therapeutics Inc.COM1,015,340$1.07M0.2%−305,813−23.1%ReducedHistory
KZRKezar Life Sciences, Inc.COM142,316$956.4K0.1%−108,862−43.3%ReducedConverted for a 1-for-10 splitHistory
CLYMClimb Bio, Inc.COM500,000$900.0K0.1%−1,000,000−66.7%ReducedHistory
RADXRadiopharm Theranostics LtdSPONSORED ADS156,171$684.0K0.1%+156,171NewHistory
ZURAZura Bio LtdCLASS A ORD SHS223,335$558.3K0.1%00.0%UnchangedHistory
CLDXCelldex Therapeutics, Inc.COM NEW9,992$252.5K<0.1%−115,008−92.0%ReducedHistory
ADGMAdagio Medical Holdings, Inc.COM213,235$223.9K<0.1%00.0%UnchangedHistory
RPTXRepare Therapeutics Inc.COM100,000$131.0K<0.1%−73,351−42.3%ReducedHistory
OMEROmeros CorpCOM9,958$98.4K<0.1%+9,958NewHistory
QTTBQ32 Bio Inc.COM27,777$95.6K<0.1%00.0%UnchangedHistory
Immatics N.V.N44445117*W EXP 07/01/202187,204$47.1K<0.1%00.0%Unchanged–
SYRSSyros Pharmaceuticals, Inc.COM NEW150,000$34.5K<0.1%+150,000NewHistory
Rocket Pharmaceuticals, Inc.77313F114*W EXP 09/02/20275,000$2.57K<0.1%00.0%Unchanged–

Options (10)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Affinity Asset Advisors, LLC in Q4 2024
SecurityClassPutsCalls
State Street SPDR S&P Biotech ETF78464A870ETF$67.5M–
MESOMesoblast LtdADR$16.6M–
AMGNAmgen IncStock–$7.82M
NMRANeumora Therapeutics, Inc.COM–$5.04M
FLNAFilana Therapeutics, Inc.COM$4.10M–
GALTGalectin Therapeutics IncCOM NEW$3.21M–
IBRXImmunityBio, Inc.COM$640.0K–
BMEABiomea Fusion, Inc.COM$582.0K–
SYRSSyros Pharmaceuticals, Inc.COM NEW$354.2K–
SLNOSoleno Therapeutics IncCOM–$8.99K

Sold out since Q3 2024 (16)

Positions held at the end of Q3 2024 that are gone from this filing.

Positions of Affinity Asset Advisors, LLC sold out since Q3 2024
SecurityClassShares in Q3 2024Value in Q3 2024% of portfolio in Q3 2024History
KURAKura Oncology, Inc.COM687,785$13.4M2.1%History
ATXSAstria Therapeutics, Inc.COM725,106$7.98M1.2%History
ONCBeOne Medicines Ltd.ADR35,000$7.86M1.2%History
TERNTerns Pharmaceuticals, Inc.COM600,000$5.00M0.8%History
SWTXSpringWorks Therapeutics, Inc.COM147,500$4.73M0.7%History
IMTXImmatics N.V.SHS250,000$2.85M0.4%History
ROIVRoivant Sciences Ltd.SHS201,587$2.33M0.4%History
VSTMVerastem, Inc.COM NEW400,000$1.20M0.2%History
BMRNBiomarin Pharmaceutical IncCOM15,000$1.05M0.2%History
PBYIPuma Biotechnology, Inc.COM250,000$637.5K0.1%History
KYTXKyverna Therapeutics, Inc.COM119,900$586.3K0.1%History
VYGRVoyager Therapeutics, Inc.COM51,727$302.6K<0.1%History
MTVAMetaVia Inc.COM89,222$282.8K<0.1%History
GNLXGENELUX CorpCOM100,000$237.0K<0.1%History
WHWKWhitehawk Therapeutics, Inc.COM47,019$96.9K<0.1%History
PMNProMIS Neurosciences Inc.COM30,643$38.3K<0.1%History